PR Newswire Clinical TrialsOriginal article
Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B
Phase 2MixedBRII-179Neutral
AI Analysis
Summary
Brii Bio announced end-of-treatment data from Phase 2b ENRICH and ENHANCE studies for BRII-179 in chronic hepatitis B, with ENRICH demonstrating higher HBsAg loss rates but ENHANCE failing to show improved response.
Clinical Trial Data
Phase
2b
Outcome Details
ENRICH study demonstrated higher HBsAg loss rates consistent with ENSURE Cohort 4; ENHANCE study did not demonstrate improved HBsAg loss rates compared to control
Importance:6/10
Sentiment:
0.20
hepatitis bfunctional curephase 2bend-of-treatment datahbsag loss
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on July 3, 2026 12:00 AM